1. Overall Survival (Time Frame - At 12 months after start of treatment): Overall Survival rate
Secondary outcome:
1. Patient and disease profiles at start of treatment with encorafenib plus cetuximab (Time Frame - Baseline): Demographic and disease chracteristics
2. BRAF-mutation assessment (Time Frame - Baseline): Date and type of BRAFV600E testing
3. Type and sequence of treatments before and after encorafenib plus cetuximab (Time Frame - Through study completion, an average of 17 months): Treatment sequence prior to and after encorafenib plus cetuximab
4. Characteristics of treatment with encorafenib plus cetuximab (Time Frame - Through encorafenib plus cetuximab treatment completion, an average of 9 months): Evaluation of reason for treatment selection (efficacy, safety profile, quality of life, patients preference, physician's preference, comorbidities, other)
5. Effectiveness of treatment with encorafenib and cetuximab (Time Frame - Through encorafenib plus cetuximab treatment completion, an average of 9 months): Further Overall Survival parameters
6. Effectiveness of treatment with encorafenib and cetuximab (Time Frame - Through encorafenib plus cetuximab treatment completion, an average of 9 months): Best observed tumor response
7. Effectiveness of treatment with encorafenib and cetuximab (Time Frame - Through encorafenib plus cetuximab treatment completion, an average of 9 months): Time to progression
8. Effectiveness of treatment with encorafenib and cetuximab (Time Frame - Through encorafenib plus cetuximab treatment completion, an average of 9 months): Overall response rate
9. Effectiveness of treatment with encorafenib and cetuximab (Time Frame - Through encorafenib plus cetuximab treatment completion, an average of 9 months): Duration of response
10. Effectiveness of treatment with encorafenib and cetuximab (Time Frame - Through encorafenib plus cetuximab treatment completion, an average of 9 months): Progression-free-survival
11. Effectiveness of treatment with encorafenib and cetuximab (Time Frame - Through encorafenib plus cetuximab treatment completion, an average of 9 months): Disease control rate
12. Effectiveness of treatment with encorafenib and cetuximab (Time Frame - Through encorafenib plus cetuximab treatment completion, an average of 9 months): Duration of disease control
13. Patient reported outcomes during treatment with encorafenib plus cetuximab - evaluated with EORTC QLQ C-30 (Time Frame - Through encorafenib plus cetuximab treatment completion, an average of 9 months): EORTC QLQ C-30 questionnaires (European Organisation for Research and Treatment of Cancer Quality of Life C-30 questionnaires) to assess quality of life of cancer patients; comprises 30 items, 24 of which are aggregated into nine multi-item scales, that is, five functioning scales (physical, role, cognitive, emotional and social), three symptom scales (fatigue, pain and nausea/vomiting) and one global health status scale. The remaining six single-item (dyspnoea, appetite loss, sleep disturbance, constipation, diarrhoea and the financial impact) scales assess symptoms. Only in case of prospective inclusion.
14. Patient's treatment satisfaction - overall (Time Frame - Through encorafenib plus cetuximab treatment completion, an average of 9 months): 4-point scale: very satisfied, satisfied, dissatisfied, very dissatisfied
15. Physician's treatment satisfaction - differentiated by efficiency, safety and overall (Time Frame - Through encorafenib plus cetuximab treatment completion, an average of 9 months): 4-point scale: very satisfied, satisfied, dissatisfied, very dissatisfied
16. Safety and tolerability of treatment with encorafenib and cetuximab - Adverse events and adverse reactions including time to onset and time to resolution (Time Frame - Through encorafenib plus cetuximab treatment completion, an average of 9 months): Number of patients with Adverse Events and maximum grade per patient, Adverse Drug Reactions, Adverse Drug Reactions grade 3/4, Serious Adverse Events, Serious Adverse Drug Reactions
17. Treatment duration (Time Frame - Through encorafenib plus cetuximab treatment completion, an average of 9 months): From date to first treatment until date of last treatment (single compounds and whole treatment)
18. Treatment dose intensity (Time Frame - Through encorafenib plus cetuximab treatment completion, an average of 9 months): From date to first treatment until date of last treatment (single compounds and whole treatment)
19. Number of treatment interruptions (Time Frame - Through encorafenib plus cetuximab treatment completion, an average of 9 months): From date to first treatment until date of last treatment (single compounds and whole treatment)
20. Duration of treatment interruptions (Time Frame - Through encorafenib plus cetuximab treatment completion, an average of 9 months): From date to first treatment until date of last treatment (single compounds and whole treatment)
